Long-term Resolution of Comorbidites After Gastric Bypass
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 25,000
- 试验地点
- 1
- 主要终点
- Change in comorbid conditions, as defined by use of pharmacological treatment
研究概览
简要总结
To evaluate effect on comorbid disease and weight loss in the long-term (>five years) after Roux-en-Y gastric bypass (RYGB) surgery for severe obesity.
详细描述
Individuals with severe obesity frequently have comorbid diseases, e.g. diabetes, hypertension, hyperlipidemia, and sleep apnea. We will study the remission rate and weight loss in the long-term (10 years) after Roux-en-Y gastric bypass (RYGB) surgery in a nationwide large group of patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Registered individuals in Scandinavian Obesity Surgery Registry (SOReg) having had gastric bypass
排除标准
- •All other operations
结局指标
主要结局
Change in comorbid conditions, as defined by use of pharmacological treatment
时间窗: 10 years
Remission of diabetes mellitus, hypertension, dyslipidemia, and depression as defined by use of pharmacological treatment, and sleep apnea as defined by use of CPAP. Data will be collected from SOReg.
次要结局
- Weight loss(10 years)
- BMI loss(10 years)
- Number of patients with pathological laboratory data (corresponding to the studied comorbid conditions)(10 years)
